Tuesday, Sep 22, 2020 | Last Update : 07:19 AM IST

182nd Day Of Lockdown

Maharashtra122438091634833015 Andhra Pradesh6317495518215410 Tamil Nadu5473374919718871 Karnataka5268764233778145 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1726081419301042 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Life   Health  09 Aug 2018  Genetic mutations may impact cancer treatment

Genetic mutations may impact cancer treatment

ANI
Published : Aug 9, 2018, 12:31 pm IST
Updated : Aug 9, 2018, 12:31 pm IST

A mutation in the gene GNAS was found to be quite frequent in appendix cancer.

Representational Image. (Photo: Pixabay)
 Representational Image. (Photo: Pixabay)

Washington: Turns out, genetic mutations in appendix cancer are distinct from those found in colon cancer and that mutations in the genes are good predictors of survival among people with appendix cancer.

To understand why some patients with appendix cancer respond to standard treatment while others do not, researchers at the University of California performed genetic profiling on appendiceal tumors to compare mutations present in both cancer types.

 

"For tumors that are rare like appendix cancer, obtaining molecular profiles will help identify potential treatment options since we don't have the clinical trial data to help guide treatments as we do in common tumors," said lead author John Paul Shen.

The retrospective study found that appendix cancer is comprised of five distinct subtypes- mucinous adenocarcinomas (46 percent), adenocarcinomas (30 percent), goblet cell carcinoids (12 percent), pseudomyxoma peritonei (7.7 percent) and signet ring cell carcinomas (5.2 percent).

A mutation in the gene GNAS, rare in colon cancer, was found to be quite frequent in appendix cancer, especially in mucinous adenocarcinomas (52 percent) and pseudomyxoma peritonei (72 percent). Patients with tumors harboring a GNAS mutation had a median survival of almost 10 years, while those whose tumors had a TP53 mutation had a median survival of only three years.

 

Understanding the molecular differences between the subtypes of appendiceal tumors is an important stepping stone for future clinical trials to develop and test different therapeutic approaches that are specific to this disease.

The findings of the study published in the Journal of JCO Precision Oncology.

Tags: genes, cancer, health, diseases, tumours